Back to search

Belgium· BE-AMP-SAM525217-00

Elebrato Ellipta 92 µg/dose - 22 µg/dose

A vilanterol, umeclidinium bromid und fluticason furoat product containing umeclidinium bromide, registered in Belgium by GlaxoSmithKline Trading Services. The same ATC class is registered in 11 of our 19 countries.

ATC R03AL08

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedElebrato Ellipta 92 µg/dose - 22 µg/d…ATCR03AL08REGISTER NO.BE-AMP-SAM525217-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Vilanterol, umeclidinium bromid und fluticason furoat is registered in 11 of 19 countries.

Countries holding a registration under ATC R03AL08 (vilanterol, umeclidinium bromid und fluticason furoat), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Vilanterol, umeclidinium bromid und fluticason furoat · ATC R03AL08

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Umeclidinium Bromide
Manufacturer
GlaxoSmithKline Trading Services
Country
Belgium (BE)
ATC code
R03AL08
ATC class
Vilanterol, Umeclidinium bromid und Fluticason furoat
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Vilanterol, umeclidinium bromid und fluticason furoat in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vilanterol, umeclidinium bromid und fluticason furoat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Incruse Ellipta, Rolufta Ellipta
  • Liechtenstein · Incruse Ellipta, Rolufta Ellipta
  • Norway · Incruse Ellipta, Rolufta Ellipta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4149407f-dfd8-4456-a302-28698a47ad87
GET /v1/drugs/4149407f-dfd8-4456-a302-28698a47ad87?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Inhalation powder, pre-dispensed",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Elebrato Ellipta 92 µg/dose - 22 µg/dose",
  "name_fr": "Elebrato Ellipta 92 µg/dose - 22 µg/dose",
  "name_nl": "Elebrato Ellipta 92 µg/dose - 22 µg/dose",
  "amp_code": "SAM525217-00",
  "strengths": [
    "65.0000",
    "55.0000",
    "22.0000",
    "92.0000",
    "25.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Umeclidinium Bromide",
    "Umeclidinium",
    "Vilanterol Trifenatate",
    "Vilanterol",
    "Fluticasone Furoate",
    "Lactose Monohydrate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Vilanterol, Umeclidinium Bromide and Fluticasone Furoate",
  "authorisation_numbers": [
    "EU/1/17/1237/003",
    "EU/1/17/1237/002",
    "EU/1/17/1237/001"
  ]
}

See everything about vilanterol, umeclidinium bromid und fluticason furoat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.